Disc Medicine, Inc. (NASDAQ:IRON) Insider Rahul Khara Sells 7,500 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 7,500 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $55.54, for a total value of $416,550.00. Following the transaction, the insider now directly owns 14,035 shares of the company's stock, valued at $779,503.90. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Thursday, January 2nd, Rahul Khara sold 7,500 shares of Disc Medicine stock. The shares were sold at an average price of $62.75, for a total transaction of $470,625.00.

Disc Medicine Stock Performance

Shares of NASDAQ IRON traded down $1.47 during trading hours on Friday, reaching $54.82. 356,954 shares of the stock were exchanged, compared to its average volume of 480,000. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -13.77 and a beta of 0.73. The stock's fifty day simple moving average is $61.15 and its 200 day simple moving average is $54.38. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15. Research analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on IRON shares. Scotiabank lifted their target price on Disc Medicine from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright reissued a "buy" rating and issued a $118.00 target price on shares of Disc Medicine in a research note on Tuesday, January 21st. Stifel Nicolaus increased their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Cantor Fitzgerald restated an "overweight" rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Raymond James upgraded shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and raised their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $88.90.

Institutional Trading of Disc Medicine

A number of institutional investors have recently modified their holdings of IRON. Raymond James Financial Inc. acquired a new position in Disc Medicine during the fourth quarter valued at approximately $5,579,000. Victory Capital Management Inc. grew its position in Disc Medicine by 7.4% in the fourth quarter. Victory Capital Management Inc. now owns 236,244 shares of the company's stock valued at $14,978,000 after acquiring an additional 16,230 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Disc Medicine by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 165,072 shares of the company's stock worth $10,466,000 after acquiring an additional 4,518 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Disc Medicine by 8.2% in the 4th quarter. Bank of New York Mellon Corp now owns 57,261 shares of the company's stock valued at $3,630,000 after purchasing an additional 4,356 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Disc Medicine by 5.7% during the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company's stock valued at $1,841,000 after purchasing an additional 1,553 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.